1. What are Antibody Drug Conjugates (ADCs)?

Antibody Drug Conjugates (ADCs) are antibody-based, anti-cancer biopharmaceuticals consisting of a monoclonal antibody carrier attached to a cytotoxic drug (or payload) via a chemical linker. The cytotoxic drug is most often conjugated through covalent bonding to specific Cysteine or Lysine residues within the antibody structure. This targeted approach allows the ADC to deliver the drug selectively to cancer cells, improving efficacy while reducing damage to healthy tissue. ADCs are being developed for cancer treatment, including acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma, and solid tumors. Their targeted mechanism makes them particularly valuable in indications where minimizing toxicity to healthy tissue, while selectively delivering the drug to targeted cells, is critical to therapeutic success.

3. How fast can you deliver results?

We regularly support ADC programs under tight IND timelines, including those preparing for or progressing through clinical trials. Our scientists will advise realistic turnaround times based on your scope and priorities.

4. How do you protect IP and data confidentiality?

We maintain strict IP protection protocols, including confidentiality agreements and secure data handling, so your sensitive data stays protected.

5. What techniques are used to confirm the biological activity of an ADC?

Biological activity is typically assessed using a combination of in vitro antibody binding assays, cell-based cytotoxicity studies, and other bioanalytical methods. While techniques like enzyme-linked immunosorbent assay (ELISA) may be used to confirm antigen binding, structural integrity and conjugation-related changes are best evaluated using techniques such as peptide mapping, mass spectrometry, and glycosylation profiling - all of which we offer in-house.

7. What factors influence ADC efficacy?

Several factors contribute to ADC efficacy, including antibody specificity, conjugation site, DAR, and payload release kinetics. The conditions within the tumor microenvironment play a major role, as they influence when and how the payload is activated. BioPharmaSpec characterizes these attributes to support ADCs through early and late-stage development.

Expert ADC Conjugation & DAR Analysis Services

Antibody-drug conjugates (ADCs) are complex molecules, and their success depends on having the right analytical insight at every stage. BioPharmaSpec provides exactly that.

We can help you understand the structural impact of conjugation on your molecule, allowing you to identify and resolve issues quickly and meet the expectations of global regulators. BioPharmaSpec provides the trusted, expert-led ADC characterization support required to advance your program with confidence.

TALK TO OUR EXPERT

How Do ADCs Work — And Why Is Characterization So Important?

ADCs represent a powerful form of targeted cancer therapy, designed to selectively attack tumor cells while sparing healthy tissue - a key advantage over traditional chemotherapies. The mechanism of action involves the monoclonal antibody component binding to a target antigen on cancer cells, triggering internalization of the ADC. Once inside the cell, the cytotoxic payload is released, killing cancer cells from within.

Characterizing an ADC molecule’s drug-to-antibody ratio (DAR), conjugation sites, and any structural changes post-conjugation is critical because these factors directly influence the ADC’s ability to deliver its therapeutic effect safely and consistently. High DAR values, for example, may improve potency but also increase the risk of off-target toxicity. Detailed structural analysis ensures your ADC functions as intended, supports regulatory expectations, and lays the foundation for consistent clinical efficacy.

Our ADC Characterization Capabilities

Our expert team delivers end-to-end analytical support tailored to your ADC development stage. When characterizing an ADC it is usual to characterize the native antibody in parallel to allow direct comparison of the conjugated and unconjugated molecules. Through this comparison, our scientists can make an assessment of any effect the conjugation process may have had on the antibody’s structure (and potential functionality).

1. Structural & Physicochemical Characterization

2. Drug-to-Antibody Ratio (DAR) Analysis

3. Site Specific Conjugation Analysis

4. ADC Stability & Aggregation Analysis

5. Broader Protein Characterization Support

Structural Characterization

Physicochemical and Biophysical

Discuss your specific ADC format with us, and our scientists can tailor the workflow to support your regulatory strategy, comparability studies, and process development needs.

Why Choose BioPharmaSpec?

Industry-Leading Expertise: Our scientists have over 30 years of experience in monoclonal antibody characterization across therapeutic classes and expression systems.
End-to-End Analytical Partnership: As well as providing full structural characterization of your ADC, we help you understand and interpret the structural data to help you meet regulatory expectations and de-risk your clinical development program.
Regulatory-Driven Deliverables: Our methods are designed to meet the expectations of global regulatory bodies.
Advanced Instrumentation: Clients benefit from our investment in state-of-the-art mass spectrometry, LC-MS/MS, and complementary techniques, combined with proprietary workflows refined through years of ADC experience. This allows a thorough and detailed investigation into all aspects of ADC structure with an application of orthogonal methodologies, an approach that is highly regarded by the regulatory authorities.

TALK TO OUR EXPERT

How Our Process Works

Consultation: You will speak directly with our scientists to discuss your ADC format, clinical development stage, regulatory priorities, and any specific challenges or concerns. We advise on the most appropriate analytical strategy for your needs.
Custom proposal: Following consultation, we provide a detailed proposal outlining the scope of work, recommended analytical methods, deliverables, timelines and project costs.
Sample analysis: All analysis is performed by BioPharmaSpec’s in-house team using qualified methods and state-of-the-art mass spectrometry and complementary techniques. Your samples remain fully secure under our strict confidentiality protocols.
Clear, actionable reporting: You will receive a comprehensive, structured report that presents your data clearly and accurately.
Ongoing support: Many clients choose to partner with us long term, relying on our expertise for comparability studies, troubleshooting, and ongoing support as their ADC program progresses.

Speak to our scientists today to discuss how we can support your ADC development.

Ready to Accelerate Your ADC Program?

If you need trusted, expert-led ADC characterization to accelerate your development and support your regulatory goals, we are ready to help. Speak directly with our scientists to discuss your molecule and receive a tailored proposal.

Frequently Asked Questions

What are Antibody Drug Conjugates (ADCs)?

Antibody Drug Conjugates (ADCs) are antibody-based, anti-cancer biopharmaceuticals consisting of a cytotoxic drug (or payload) attached to a monoclonal antibody carrier via a chemical linker.

The cytotoxic drug is most often conjugated through covalent bonding to specific Cysteine or Lysine residues within the antibody structure. This targeted approach allows the ADC to deliver the drug selectively to cancer cells via the binding specificity of the monoclonal antibody carrier, improving drug efficacy while reducing damage to healthy tissue.

ADCs are being developed for cancer treatment, including acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma, and solid tumors. Their targeted mechanism makes them particularly valuable in indications where minimizing toxicity to healthy tissue, while selectively delivering the drug to targeted cells, is critical to therapeutic success.

What ADC characterization methods do I need to perform?

For any ADC program, it is essential to characterize both the native antibody and the ADC itself in parallel. This allows you to directly compare structural and functional attributes, and demonstrate whether conjugation has impacted the antibody, which is a key regulatory expectation.

At minimum, your ADC characterization should include drug-to-antibody ratio (DAR) analysis, conjugation site identification, attachment site occupancy, stability studies, and assessment of any structural changes to the monoclonal antibody post-conjugation as well as assessments of any likely reaction by-products of the linker or drug.

In addition to these ADC-specific analyses, BioPharmaSpec provides the full suite of structural, physicochemical, and biophysical characterization methods required under ICH guidelines, including comprehensive product and process impurity testing and host cell protein (HCP) analysis by LC-MS. We can help you define the most appropriate scope of analysis based on your molecule, development stage, and regulatory objectives.

How fast can you deliver results?

How do you protect IP and data confidentiality?

How is the number of conjugated drugs per antibody determined?

What factors influence ADC efficacy?

Our Expert

Michael-John O’Connor

Michael-John (MJ) is Director of Biochemical Services at BioPharmaSpec and has extensive experience applying mass spectrometry to biosimilar comparability studies.

Case Study

Iksuda Therapeutics – Assessment of Drug Antibody Ratios (DARs)

Iksuda requested an assessment of DARs for their antibody-drug-conjugate (ADC) product in plasma samples derived from mouse Pharmacokinetic (PK) studies.

Knowledge Center